Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Onglyza

This page shows the latest Onglyza news and features for those working in and with pharma, biotech and healthcare.

FDA won't add outcomes data to Januvia label

FDA won't add outcomes data to Januvia label

Those concerns have caused warnings to be imposed on some rival drugs, namely AstraZeneca's Onglyza (saxagliptin) and Takeda's Nesina (alogliptin).

Latest news

  • AZ gets US approval for diabetes combo Qtern AZ gets US approval for diabetes combo Qtern

    Wins licensing for Onglyza/Farxiga dual-therapy after rejection by the FDA in 2015. ... Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) and SGLT2 inhibitor Farxiga/Forixiga

  • EU clears AZ's FDA-rejected diabetes combination EU clears AZ's FDA-rejected diabetes combination

    Qtern combines the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) with SGLT2 inhibitor Farxiga/Forixiga (saxagliptin), and is the second drug of its type on the market after ... Since then however, Onglyza and certain other DPP4

  • NICE backs freer use of SGLT2 inhibitors for diabetes NICE backs freer use of SGLT2 inhibitors for diabetes

    Importantly the recommendations put the SGLT2 inhibitors on a par with another newer class of diabetes drug - DPP-4 inhibitors such as MSD's Januvia (sitagliptin) and AstraZeneca's Onglyza (saxagliptin).

  • FDA rejects AZ's diabetes combination FDA rejects AZ's diabetes combination

    The combination of DPP-4 inhibitor saxagliptin - sold by AZ as Onglyza - and SGLT2 inhibitor dapagliflozin (marketed as Farxiga/Forixiga) is considered to be a key component of the company's

  • The role of pharma in the digital world of patient and doctors The role of pharma in the digital world of patient and doctors

    For us, that would be going to a website after being diagnosed with diabetes [AZ markets type II oral medicines Forxiga, Byetta, Bydureon and Onglyza], and make sure that here, we

More from news
Approximately 10 fully matching, plus 46 partially matching documents found.

Latest Intelligence

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... As AZ can attest

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Quick links

Infographics

Multimedia